BSE Live
Apr 02, 16:01Prev. Close
156.35
Open Price
155.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Makers Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 7.87 | -11.78 | -10.58 | 0.35 | -3.29 | |
| Diluted EPS (Rs.) | 7.87 | -11.78 | -10.58 | 0.35 | -3.29 | |
| Cash EPS (Rs.) | 12.69 | -7.18 | -6.71 | 4.23 | 5.25 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 95.04 | 87.19 | 98.78 | 102.30 | 100.92 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 95.04 | 87.19 | 98.78 | 102.30 | 100.92 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 72.78 | 83.20 | 72.11 | 106.59 | 90.32 | |
| PBDIT/Share (Rs.) | 14.77 | -4.42 | -5.08 | 7.92 | 7.55 | |
| PBIT/Share (Rs.) | 9.95 | -9.02 | -9.14 | 4.04 | -0.99 | |
| PBT/Share (Rs.) | 8.35 | -11.79 | -11.48 | 0.64 | -4.22 | |
| Net Profit/Share (Rs.) | 7.87 | -11.78 | -10.78 | 0.35 | -3.29 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 20.29 | -5.31 | -7.04 | 7.43 | 8.35 | |
| PBIT Margin (%) | 13.66 | -10.84 | -12.68 | 3.79 | -1.09 | |
| PBT Margin (%) | 11.47 | -14.17 | -15.92 | 0.59 | -4.67 | |
| Net Profit Margin (%) | 10.80 | -14.16 | -14.95 | 0.32 | -3.64 | |
| Return on Networth / Equity (%) | 8.27 | -13.51 | -10.91 | 0.34 | -3.25 | |
| Return on Capital Employed (%) | 10.13 | -8.81 | -8.44 | 3.56 | -0.83 | |
| Return on Assets (%) | 6.50 | -8.06 | -7.50 | 0.20 | -2.04 | |
| Total Debt/Equity (X) | 0.01 | 0.26 | 0.16 | 0.34 | 0.28 | |
| Asset Turnover Ratio (%) | 0.55 | 0.57 | 0.50 | 0.64 | 0.58 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.19 | 0.81 | 0.92 | 0.72 | 1.10 | |
| Quick Ratio (X) | 0.61 | 0.38 | 0.52 | 0.31 | 0.58 | |
| Inventory Turnover Ratio (X) | 4.57 | 0.73 | 0.63 | 0.63 | 0.58 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 76.37 | 79.68 | 66.78 | 106.85 | 130.99 | |
| EV/Net Operating Revenue (X) | 1.78 | 1.62 | 1.57 | 2.04 | 2.95 | |
| EV/EBITDA (X) | 8.76 | -30.54 | -22.29 | 27.43 | 35.30 | |
| MarketCap/Net Operating Revenue (X) | 1.77 | 1.35 | 1.35 | 1.71 | 2.65 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 1.36 | 1.29 | 0.99 | 1.78 | 2.37 | |
| Price/Net Operating Revenue | 1.77 | 1.35 | 1.35 | 1.71 | 2.65 | |
| Earnings Yield | 0.06 | -0.11 | -0.11 | 0.00 | -0.01 |
20.02.2026
Makers Labs Consolidated December 2025 Net Sales at Rs 35.67 crore, up 28.81% Y-o-Y
19.02.2026
Makers Labs Standalone December 2025 Net Sales at Rs 12.70 crore, up 34.43% Y-o-Y
14.11.2025
Makers Labs Consolidated September 2025 Net Sales at Rs 34.17 crore, up 15.58% Y-o-Y
12.11.2025
Makers Labs Standalone September 2025 Net Sales at Rs 12.64 crore, up 9.89% Y-o-Y
20.02.2026
Makers Labs Consolidated December 2025 Net Sales at Rs 35.67 crore, up 28.81% Y-o-Y
19.02.2026
Makers Labs Standalone December 2025 Net Sales at Rs 12.70 crore, up 34.43% Y-o-Y
14.11.2025
Makers Labs Consolidated September 2025 Net Sales at Rs 34.17 crore, up 15.58% Y-o-Y
12.11.2025
Makers Labs Standalone September 2025 Net Sales at Rs 12.64 crore, up 9.89% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth